

# Takeshi Yamamoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2076305/publications.pdf>

Version: 2024-02-01

33  
papers

1,798  
citations

331670

21  
h-index

414414

32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1217  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stabilization of RyR2 maintains right ventricular function, reduces the development of ventricular arrhythmias, and improves prognosis in pulmonary hypertension. <i>Heart Rhythm</i> , 2022, 19, 986-997.	0.7	7
2	Herpud1 suppress angiotensin II induced hypertrophy in cardiomyocytes. <i>Biochemistry and Biophysics Reports</i> , 2022, 30, 101248.	1.3	0
3	Dantrolene reduces platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice. <i>Biochemical and Biophysical Research Communications</i> , 2022, 623, 51-58.	2.1	1
4	Enhancing calmodulin binding to ryanodine receptor is crucial to limit neuronal cell loss in Alzheimer disease. <i>Scientific Reports</i> , 2021, 11, 7289.	3.3	14
5	Dantrolene prevents ventricular tachycardia by stabilizing the ryanodine receptor in pressure-overload induced failing hearts. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 57-63.	2.1	18
6	G790del mutation in DSC2 alone is insufficient to develop the pathogenesis of ARVC in a mouse model. <i>Biochemistry and Biophysics Reports</i> , 2020, 21, 100711.	1.3	8
7	Enhancing calmodulin binding to cardiac ryanodine receptor completely inhibits pressure-overload induced hypertrophic signaling. <i>Communications Biology</i> , 2020, 3, 714.	4.4	17
8	Dantrolene prevents hepatic steatosis by reducing cytoplasmic Ca <sup>2+</sup> level and ER stress. <i>Biochemistry and Biophysics Reports</i> , 2020, 23, 100787.	1.3	4
9	Stabilizing cardiac ryanodine receptor prevents the development of cardiac dysfunction and lethal arrhythmia in Ca <sup>2+</sup> /calmodulin-dependent protein kinase III <sup>c</sup> transgenic mice. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 431-438.	2.1	14
10	Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia. <i>JCI Insight</i> , 2019, 4, .	5.0	24
11	CaMKII-mediated phosphorylation of RyR2 plays a crucial role in aberrant Ca <sup>2+</sup> release as an arrhythmogenic substrate in cardiac troponin T-related familial hypertrophic cardiomyopathy. <i>Biochemical and Biophysical Research Communications</i> , 2018, 496, 1250-1256.	2.1	24
12	Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm</i> , 2018, 15, 905-914.	0.7	6
13	Nuclear translocation of calmodulin in pathological cardiac hypertrophy originates from ryanodine receptor bound calmodulin. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 125, 87-97.	1.9	15
14	Correction of impaired calmodulin binding to RyR2 as a novel therapy for lethal arrhythmia in the pressure-overloaded heart failure. <i>Heart Rhythm</i> , 2017, 14, 120-127.	0.7	23
15	Oxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and pathologically alter, RyR structure and calmodulin affinity. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 85, 240-248.	1.9	91
16	Enhanced binding of calmodulin to RyR2 corrects arrhythmogenic channel disorder in CPVT-associated myocytes. <i>Biochemical and Biophysical Research Communications</i> , 2014, 448, 1-7.	2.1	28
17	Enhanced binding of calmodulin to the ryanodine receptor corrects contractile dysfunction in failing hearts. <i>Cardiovascular Research</i> , 2012, 96, 433-443.	3.8	25
18	Mutation-Linked Defective Interdomain Interactions Within Ryanodine Receptor Cause Aberrant Ca <sup>2+</sup> Release Leading to Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2011, 124, 682-694.	1.6	58

#	ARTICLE	IF	CITATIONS
19	Dantrolene, a Therapeutic Agent for Malignant Hyperthermia, Inhibits Catecholaminergic Polymorphic Ventricular Tachycardia in a RyR2R2474S/+ Knock-In Mouse Model. <i>Circulation Journal</i> , 2010, 74, 2579-2584.	1.6	107
20	Norepinephrine spillover during exercise as a novel parameter to evaluate the severity of heart failure. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 868-873.	2.1	4
21	Catecholaminergic Polymorphic Ventricular Tachycardia Is Caused by Mutation-Linked Defective Conformational Regulation of the Ryanodine Receptor. <i>Circulation Research</i> , 2010, 106, 1413-1424.	4.5	138
22	Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 660-666.	2.1	69
23	Dissociation of calmodulin from cardiac ryanodine receptor causes aberrant Ca <sup>2+</sup> release in heart failure. <i>Cardiovascular Research</i> , 2010, 87, 609-617.	3.8	72
24	Dantrolene, a Therapeutic Agent for Malignant Hyperthermia, Markedly Improves the Function of Failing Cardiomyocytes by Stabilizing Interdomain Interactions Within the Ryanodine Receptor. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1993-2005.	2.8	159
25	Defective domain-domain interactions within the ryanodine receptor as a critical cause of diastolic Ca <sup>2+</sup> leak in failing hearts. <i>Cardiovascular Research</i> , 2008, 81, 536-545.	3.8	78
26	Identification of Target Domains of the Cardiac Ryanodine Receptor to Correct Channel Disorder in Failing Hearts. <i>Circulation</i> , 2008, 117, 762-772.	1.6	76
27	Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 43-52.	3.3	99
28	Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. <i>Biochemical Journal</i> , 2005, 387, 905-909.	3.7	65
29	Correction of Defective Interdomain Interaction Within Ryanodine Receptor by Antioxidant Is a New Therapeutic Strategy Against Heart Failure. <i>Circulation</i> , 2005, 112, 3633-3643.	1.6	110
30	Defective Regulation of Interdomain Interactions Within the Ryanodine Receptor Plays a Key Role in the Pathogenesis of Heart Failure. <i>Circulation</i> , 2005, 111, 3400-3410.	1.6	131
31	Identification of a Dantrolene-binding Sequence on the Skeletal Muscle Ryanodine Receptor. <i>Journal of Biological Chemistry</i> , 2002, 277, 34918-34923.	3.4	137
32	Regulation of calcium release by interdomain interaction within ryanodine receptors. <i>Frontiers in Bioscience - Landmark</i> , 2002, 7, d671-683.	3.0	116
33	Postulated Role of Inter-domain Interaction within the Ryanodine Receptor in Ca <sup>2+</sup> Channel Regulation. <i>Trends in Cardiovascular Medicine</i> , 2000, 10, 310-316.	4.9	60